Epidemiology of physician-diagnosed neuropathic pain in Brazil

被引:15
|
作者
Udall, Margarita [1 ]
Kudel, Ian [2 ]
Cappelleri, Joseph C. [3 ]
Sadosky, Alesia [1 ]
King-Concialdi, Kristen [2 ]
Parsons, Bruce [1 ]
Hlavacek, Patrick [1 ]
Hopps, Markay [1 ]
Arline Salomon, P. [4 ]
DiBonaventura, Marco D. [2 ]
Clark, Patricia [5 ,6 ]
Santos Garcia, Oio Batista [7 ]
机构
[1] Pfizer Inc, New York, NY USA
[2] Kantar Hlth, Hlth Outcomes Practice, New York, NY 10010 USA
[3] Pfizer Inc, Groton, CT 06340 USA
[4] Pfizer Inc, Bosques De Las Lomas, Mexico
[5] Hosp Infantil Mexico Dr Federico Gomez, Clin Epidemiol Unit, Mexico City, DF, Mexico
[6] Univ Nacl Autonoma Mexico, Fac Med, Mexico City, DF, Mexico
[7] Univ Fed Maranhao, Pain & Palliat Care Dept, Maranhao, Brazil
来源
JOURNAL OF PAIN RESEARCH | 2019年 / 12卷
关键词
neuropathic pain; Brazil; quality of life; pain; work productivity and activity impairment; ADULTS SEEKING TREATMENT; UNITED-STATES; GENERAL-POPULATION; BURDEN; ILLNESS; PREVALENCE; EQ-5D;
D O I
10.2147/JPR.S160504
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: Estimate the prevalence of neuropathic pain (NeP) among chronic pain patients attending Brazilian hospitals and pain clinics in Sao Paulo, Ceara, and Bahia and explore clinical characteristics by subtypes: painful diabetic peripheral neuropathy (pDPN), central neuropathic pain (CNP), chronic low back pain with a neuropathic component (CLBP-NeP), postherpetic neuralgia (PHN), post-traumatic neuropathic pain (PTN), and post-surgical neuropathic pain (PSN). Methods: Physicians screened patients reporting chronic pain for >= 3 months (n=2,118) for probable NeP, using the Douleur Neuropathique 4 questionnaire and physician assessment, and reported their NeP subtype(s), symptoms, and medications. Identified NeP patients completed a questionnaire including treatment experiences, quality of life EuroQol 5 Dimensions [EQ-5D]), pain severity and interference (Brief Pain Inventory [BPI]), and Work Productivity and Activity Impairment scales. Descriptive analyses were performed by NeP subtype. Results: The prevalence of probable NeP was 14.5% (n=307). NeP patients were mostly female (80.5%), middle-aged (mean [M]=52.5, SD=13.9), and Pardo (44.3%). Of those diagnosed with an NeP subtype (n=209), the largest proportions were CLBP-NeP (36.8%), followed by pDPN (18.7%), CNP (17.7%), PTN (17.2%), PSN (13.4%), and PHN (3.3%). Across subtypes, the most widely reported symptoms were numbness (range: 62.2%-89.7%) and hyperalgesia (range: 32.1%-76.9%) and the most commonly prescribed pain analgesics were NSA ID (range: 18.2%-57.1%), opioids (range: 0.0%-39.3%), and antiepileptics (range: 18.2%-57.1%). PTN and PSN patients reported the least favorable EQ-5D index scores (M=0.42, SD=0.19) and BPI-Pain Severity scores (M=7.0, SD=1.9), respectively. Those diagnosed with CNP had the least favorable BPI-Pain Interference scores (M=6.0, SD=2.7). Patients with PHN reported the least impairment based on EQ-5D index scores (M=0.60, SD=0.04). Those with pDPN had the most favorable BPI scores (BPI-Pain Severity: M=4.6, SD=2.3; BPI-Pain Interference: M=4.7, SD=2.7 Conclusion: Evaluation of chronic pain patients in Brazil yielded a 14.5% probable NeP prevalence. NSAIDs and opioids were commonly used, and there was a high incidence of NeP-related symptoms with varying levels of dysfunction across subtypes.
引用
收藏
页码:243 / 253
页数:11
相关论文
共 50 条
  • [41] Rhinitis Questionnaire Items Predict Physician-Diagnosed Allergic Rhinitis in Children
    Kim, H.
    Levin, L.
    LeMasters, G. K.
    Bernstein, D. I.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 127 (02) : AB254 - AB254
  • [42] Parental stress and environmental influences on children's physician-diagnosed food allergy
    Lu, Chan
    Jiang, Ying
    Wang, Lin
    Lan, Mengju
    Wang, Faming
    BUILDING AND ENVIRONMENT, 2025, 267
  • [43] Physician-Diagnosed Obesity in German 6- to 14-Year-Olds
    Eschenbeck, Heike
    Kohlmann, Carl-Walter
    Dudey, Stefan
    Schuerholz, Thomas
    OBESITY FACTS, 2009, 2 (02) : 67 - 73
  • [44] IGE LEVELS ARE LOW OR UNDETECTABLE IN PATIENTS WITH PHYSICIAN-DIAGNOSED COMMON VARIABLE IMMUNODEFICIENCY
    Borish, L.
    Hemler, J.
    Kennedy, J. L.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2011, 107 (05) : A96 - A96
  • [45] Physician-diagnosed asthma and drug utilization in the European Community Respiratory Health Survey
    Janson, C
    Chinn, S
    Jarvis, D
    Burney, P
    EUROPEAN RESPIRATORY JOURNAL, 1997, 10 (08) : 1795 - 1802
  • [46] Prevalence of self-reported physician-diagnosed systemic lupus erythematosus in the USA
    Hochberg, MC
    Perlmutter, DL
    Medsger, TA
    Steen, V
    Weisman, MH
    White, B
    Wigley, FM
    LUPUS, 1995, 4 (06) : 454 - 456
  • [47] Stabilization of an increasing trend in physician-diagnosed asthma prevalence in Saskatchewan, 1991 to 1998
    Senthilselvan, A
    Lawson, J
    Rennie, DC
    Dosman, JA
    CHEST, 2003, 124 (02) : 438 - 448
  • [48] Estrogen replacement therapy and incidence of self-reported physician-diagnosed arthritis
    Sahyoun, NR
    Brett, KM
    Hochberg, MC
    Pamuk, ER
    PREVENTIVE MEDICINE, 1999, 28 (05) : 458 - 464
  • [49] Neuropathic pain: Definition, assessment and epidemiology
    Bouhassira, D.
    REVUE NEUROLOGIQUE, 2019, 175 (1-2) : 16 - 25
  • [50] THE NEUROPATHIC PAIN DIAGNOSED WITH THE GRADING SYSTEM IS DIFFERENT FROM PAIN DEFINED WITH THE DEFINITION OF NEUROPATHIC PAIN
    Toda, Katsuhiro
    PAIN PRACTICE, 2011, 11 (06) : 583 - 584